Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy for lupus nephritis (LN). This follows the clinical trial hold placed by ...

Drug interactions, patient characteristics, and steroid use are critical in LN management, influencing treatment choices and outcomes. Nephrologists focus on renal preservation, while ...

Introduction: Lupus nephritis (LN ... In addition, the patients in the nephritis group had a significantly greater SLEDAI score. Statistically significant greater doses of steroids were administered ...

Belimumab and voclosporin have unique mechanisms of action, impacting their efficacy and safety profiles in lupus nephritis treatment. Payers consider clinical outcomes, cost, and value when ...

Lupkynis (voclosporin) is now approved in Japan to treat lupus nephritis, a complication of lupus marked by kidney damage and inflammation. The Japanese Ministry of Health, Labour, and Welfare ...

The Lupus Foundation of America (LFA) is dedicated to reducing time to diagnosis, and one program that directly tackles this is Be Fierce. Take Control. The campaign targets young Hispanic/Latina and ...

The company had voluntary suspended subject enrolment and dosing in the Phase II PALIZADE trial of zetomipzomib.

"We are thrilled to achieve this milestone that will provide access to LUPKYNIS in Japan, where there is a high rate of lupus nephritis among ... It is the only clinical program to include three ...

At its most advanced stages, the kidney damage that lupus nephritis causes can only be treated through transplantation or dialysis. Gazyva is an intravenously administered monoclonal antibody that ...

The FDA has placed Kezar Life Sciences’ lupus trial on hold after the biotech flagged four deaths during the phase 2b study.